10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,337,847 | $123,438,322 | -5% | 0.58% |
| 2. | 2,200,000 | $116,160,000 | +120% | 1.85% | |
| 3. | Armistice Capital Steven Boyd | 1,896,575 | $100,139,160 | -9% | 1.6% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,873,701 | $98,931,412 | +12% | 0.12% |
| 5. | Partner Fund Management Christopher Medlock James | 1,757,192 | $92,779,738 | 5.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | Director | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | Large Shareholder | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | Large Shareholder | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | Large Shareholder | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | Large Shareholder | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $48.61 | 742 | Director | 24,559 | 2024-12-16 | Filing | |
| $50.42 | 1,780 | Director | 38,461 | 2024-12-11 | Filing | |
| $50.65 | 2,000 | Officer | 116,071 | 2024-12-10 | Filing | |
| $50.63 | 5,300 | Officer | 118,071 | 2024-12-10 | Filing | |
| $50.76 | 5,000 | Officer, Director | 397,678 | 2024-12-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,102,070 | $1,344,361,823 | 0.03% | |
| 2. | 13,007,783 | $1,086,019,844 | 0.08% | |
| 3. | 11,016,889 | $919,800,063 | 0.02% | |
| 4. | 6,488,500 | $541,724,865 | 0.1% | |
| 5. | 5,893,358 | $492,036,459 | 0.02% |
News See All
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript November 6, 2024Cytokinetics, Incorporated misses on earnings expectations.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
7 Best Small Company Stocks To Invest In
The Fed's decision to cut interest rates by 50 basis points in September significantly impacted the market.
Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy...
7 Best Mid-Cap Healthcare Stocks To Buy Now
The healthcare industry is considered to be a fairly defensive sector due to its need.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2023 Earnings Call Transcript
Cytokinetics, Incorporated misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-1.03.
5 Best Russell 2000 Stocks To Buy According To Hedge Funds
In this article, we discuss 5 best Russell 2000 stocks to buy.
Billionaire Hedge Funds
